These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 37477127)

  • 1. Muscle invasive bladder cancer: where is the field headed?
    Ghatalia P; Kaur J; Sonpavde G
    Expert Opin Biol Ther; 2023; 23(9):913-927. PubMed ID: 37477127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Effectiveness of Neoadjuvant Pembrolizumab Versus Cisplatin-based Chemotherapy or Upfront Radical Cystectomy in Patients with Muscle-invasive Urothelial Bladder Cancer.
    Li R; Nocera L; Rose KM; Raggi D; Naidu S; Mercinelli C; Cigliola A; Tateo V; Patanè D; Grass GD; Gilbert SM; Sexton WJ; Bandini M; Moschini M; Briganti A; Montorsi F; Spiess PE; Necchi A
    Eur Urol Oncol; 2024 Jun; 7(3):614-624. PubMed ID: 38184473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant and adjuvant treatments in muscle-invasive bladder cancer: Where are we?
    Osanto S; Álvarez Gómez de Segura C
    Arch Esp Urol; 2020 Dec; 73(10):971-985. PubMed ID: 33269716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant therapy for muscle-invasive bladder cancer.
    Jain RK; Sonpavde G
    Expert Rev Anticancer Ther; 2020 Jul; 20(7):603-614. PubMed ID: 32546025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PrECOG PrE0807: A Phase 1b Feasibility Trial of Neoadjuvant Nivolumab Without and with Lirilumab in Patients with Muscle-invasive Bladder Cancer Ineligible for or Refusing Cisplatin-based Neoadjuvant Chemotherapy.
    Grivas P; Koshkin VS; Chu X; Cole S; Jain RK; Dreicer R; Cetnar JP; Sundi D; Gartrell BA; Galsky MD; Woo B; Li-Ning-Tapia E; Hahn NM; Carducci MA
    Eur Urol Oncol; 2024 Aug; 7(4):914-922. PubMed ID: 38155060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SEOM-SOGUG clinical guideline for localized muscle invasive and advanced bladder cancer (2021).
    Valderrama BP; González-Del-Alba A; Morales-Barrera R; Peláez Fernández I; Vázquez S; Caballero Díaz C; Domènech M; Fernández Calvo O; Gómez de Liaño Lista A; Arranz Arija JÁ
    Clin Transl Oncol; 2022 Apr; 24(4):613-624. PubMed ID: 35347572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy.
    Pietzak EJ; Zabor EC; Bagrodia A; Armenia J; Hu W; Zehir A; Funt S; Audenet F; Barron D; Maamouri N; Li Q; Teo MY; Arcila ME; Berger MF; Schultz N; Dalbagni G; Herr HW; Bajorin DF; Rosenberg JE; Al-Ahmadie H; Bochner BH; Solit DB; Iyer G
    Eur Urol; 2019 Feb; 75(2):231-239. PubMed ID: 30290956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder.
    Rouanne M; Bajorin DF; Hannan R; Galsky MD; Williams SB; Necchi A; Sharma P; Powles T
    Eur Urol Oncol; 2020 Dec; 3(6):728-738. PubMed ID: 33177001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of immunotherapy in localized muscle invasive urothelial cancer.
    Kaur J; Choi W; Geynisman DM; Plimack ER; Ghatalia P
    Ther Adv Med Oncol; 2021; 13():17588359211045858. PubMed ID: 34567274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current Status of Perioperative Therapy in Muscle-Invasive Bladder Cancer and Future Directions.
    Cockrell DC; Rose TL
    Curr Oncol Rep; 2023 May; 25(5):511-520. PubMed ID: 36897554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic therapy issues: Immunotherapy in nonmetastatic urothelial cancer.
    Nadal R; Apolo AB; Girardi DM; Hahn NM; Bellmunt J
    Urol Oncol; 2023 Jan; 41(1):27-34. PubMed ID: 34756410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perioperative pembrolizumab therapy in muscle-invasive bladder cancer: Phase III KEYNOTE-866 and KEYNOTE-905/EV-303.
    Galsky MD; Hoimes CJ; Necchi A; Shore N; Witjes JA; Steinberg G; Bedke J; Nishiyama H; Fang X; Kataria R; Sbar E; Jia X; Siefker-Radtke A
    Future Oncol; 2021 Aug; 17(24):3137-3150. PubMed ID: 34008425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Open-label phase II to evaluate the efficacy of NEoadjuvant dose-dense MVAC In cOmbination with durvalumab and tremelimumab in muscle-invasive urothelial carcinoma: NEMIO.
    Thibault C; Elaidi R; Vano YA; Rouabah M; Braychenko E; Helali I; Audenet F; Oudard S
    Bull Cancer; 2020 Jun; 107(5S):eS8-eS15. PubMed ID: 32620213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spatial Relationships in the Tumor Microenvironment Demonstrate Association with Pathologic Response to Neoadjuvant Chemoimmunotherapy in Muscle-invasive Bladder Cancer.
    Beckabir W; Wobker SE; Damrauer JS; Midkiff B; De la Cruz G; Makarov V; Flick L; Woodcock MG; Grivas P; Bjurlin MA; Harrison MR; Vincent BG; Rose TL; Gupta S; Kim WY; Milowsky MI
    Eur Urol; 2024 Mar; 85(3):242-253. PubMed ID: 38092611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urothelial carcinoma in situ response to cisplatin-based neoadjuvant chemotherapy, or lack thereof: Impact on patient selection for organ preservation in muscle-invasive disease?
    Tachibana I; Bandali E; Calaway AC; Krishnan N; Cheng L; Adra N; Kaimakliotis HZ
    Urol Oncol; 2020 Nov; 38(11):850.e1-850.e7. PubMed ID: 32693973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune features are associated with response to neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer.
    Beckabir W; Zhou M; Lee JS; Vensko SP; Woodcock MG; Wang HH; Wobker SE; Atassi G; Wilkinson AD; Fowler K; Flick LM; Damrauer JS; Harrison MR; McKinnon KP; Rose TL; Milowsky MI; Serody JS; Kim WY; Vincent BG
    Nat Commun; 2024 May; 15(1):4448. PubMed ID: 38789460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment Approaches for Cisplatin-Ineligible Patients with Invasive Bladder Cancer.
    Einstein DJ; Sonpavde G
    Curr Treat Options Oncol; 2019 Feb; 20(2):12. PubMed ID: 30741358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II clinical trial of neoadjuvant sasanlimab and stereotactic body radiation therapy as an
    Satkunasivam R; Lim K; Teh BS; Guzman J; Zhang J; Farach A; Chen SH; Wallis CJ; Efstathiou E; Esnaola NF; Sonpavde GP
    Future Oncol; 2022 Aug; 18(25):2771-2781. PubMed ID: 35703113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perioperative systemic therapy in muscle invasive bladder cancer: Current standard method, biomarkers and emerging strategies.
    Kim KH; Lee HW; Ha HK; Seo HK
    Investig Clin Urol; 2023 May; 64(3):202-218. PubMed ID: 37341001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perioperative Immunotherapy in Muscle-Invasive Bladder Cancer.
    Singh A; Osbourne AS; Koshkin VS
    Curr Treat Options Oncol; 2023 Sep; 24(9):1213-1230. PubMed ID: 37428331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.